Society for Clinical Research Sites Names PPD Winner of Prestigious Eagle Award
06 Ottobre 2021 - 3:00PM
Business Wire
PPD, Inc. (Nasdaq: PPD) is the recipient of the 2021 Eagle Award
from the Society for Clinical Research Sites (SCRS) for its
commitment to advancing clinical research professionalism through
strong site partnerships.
The award, based on voting by research sites globally,
recognizes the contract research organization (CRO) that best
exemplifies a site-focused approach to clinical trial management by
demonstrating outstanding leadership, professionalism and
integrity.
“The Eagle Award is one of the most prestigious honors in our
industry, and this recognition affirms PPD’s ongoing commitment to
create and sustain strong relationships with our site partners,”
said David Johnston, Ph.D., executive vice president and global
head of clinical development services at PPD. “In close
coordination with our site partners and customers, we are committed
to upholding the highest standards in clinical trial management to
help deliver life-changing therapies for patients. We want to thank
the sites and their research teams for their collaborative
partnership as we progress our shared vision.”
PPD draws on decades of experience in collaborating with leading
research sites and site networks worldwide to advance
biopharmaceutical and biotech customers’ development programs. For
investigators and physician practices new to clinical research, PPD
offers SiteCoach, customized training to help them navigate the
complexities of patient recruitment, educate patients on their
options and streamline trial administration. Additionally, PPD’s
Accelerated Enrollment Solutions business (AES) provides customers
access to its dedicated site network of more than 160 global
sites.
SCRS site members nominated companies for the Eagle Award that
they had worked with in the past year that exemplified excellence,
and PPD was selected based on votes cast from the global site
community. PPD accepted the award during the annual SCRS Global
Site Solutions Summit in Hollywood, Florida.
“The SCRS Eagle Award recognizes a sponsor and CRO who have
exemplified an exceptional working relationship with clinical
research sites,” said Sean Soth, vice president of global business
partnerships at SCRS. “Collaboration on study design, responsive
communication and fair contracting practices are among the elements
that are weighed in the SCRS Eagle Award voting process. This year,
nearly 5,000 sites participated in voting and recognized PPD as the
2021 CRO recipient. SCRS congratulates PPD for their contributions
to site success globally."
SCRS, a global organization founded in 2012, is an influential
voice for the clinical research site community and an active
partner in industry-wide initiatives and dialogues focused on
improving the clinical research enterprise. SCRS represents more
than 9,500 sites in 47 countries, providing members with a
community dedicated to advocacy, education, mentorship and
connectivity.
About PPD
PPD is a leading global contract research organization providing
comprehensive, integrated drug development, laboratory and
lifecycle management services. Our customers and partners include
pharmaceutical, biotechnology, medical device, academic and
government organizations. With more than 30,000 professionals
worldwide, PPD has conducted clinical trials in more than 100
countries to help customers deliver life-changing therapies to
improve health. We apply innovative technologies, therapeutic
expertise and a firm commitment to quality to bend the cost and
time curve of drug development and optimize value. For more
information, visit www.ppd.com.
This news release contains forward-looking statements. These
statements often include words such as “expect,” “believe,”
“project,” “forecast,” “estimate,” “target” and other similar
expressions. Although we believe these forward-looking statements
are based on reasonable assumptions at the time they are made, you
should be aware that many factors could affect our actual financial
results, and therefore actual results might differ materially from
those expressed in the forward-looking statements. Factors that
might materially affect such forward-looking statements include,
but are not limited to, the fragmented and highly competitive
nature of the drug development services industry; changes in trends
in the biopharmaceutical industry; our ability to keep pace with
rapid technological changes that could make our services less
competitive or obsolete; political, economic and/or regulatory
influences and changes; the risks related to the proposed merger of
PPD by Thermo Fisher Scientific Inc.; and other factors disclosed
under the “Risk Factors” section in our periodic reports filed with
the Securities and Exchange Commission (SEC), including our latest
Annual Report on Form 10-K and Quarterly Report on form 10-Q, which
are available on our website at https://investors.ppd.com or the
SEC’s website at www.sec.gov. We assume no obligation and disclaim
any duty to revise or update any forward-looking statements, or
make any new forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211006005617/en/
PPD Contacts Media: Nadine Maeser +1 919 456 4425
media@ppd.com Investors: Tracy Krumme +1 910 558 4186
investors@ppd.com
Grafico Azioni Pharmaceutical Product Developme (NASDAQ:PPDI)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Pharmaceutical Product Developme (NASDAQ:PPDI)
Storico
Da Ott 2023 a Ott 2024